Express Scripts, one of the nation’s largest pharmacy benefit managers, reportedly plans to include Novo Nordisk‘s (NYSE:NVO) once-weekly Type II diabetes, Ozempic, on its 2018 formulary.
The move puts Ozempic directly in competition with Eli Lilly‘s (NYSE:LLY) once-weekly Trulicity drug. Both products will also go up against AstraZeneca‘s (NYSE:AZN) once-weekly Bydureon medication.
Get the full story at our sister site, Drug Delivery Business News.
The post Express Scripts to include Novo Nordisk’s once-weekly diabetes drug on 2018 formulary appeared first on MassDevice.
from MassDevice http://ift.tt/2sGbyjw
Cap comentari:
Publica un comentari a l'entrada